AI주식인사이트AI Stock Insight
D

진원생명과학

011000KOSPI의약품 제조업

39.8 / 100

Reference Date: 2026-06-10

Financial Score5.0 / 40
News Sentiment15.8 / 25
Momentum7.0 / 20
Disclosure12.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Rose 11.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Jinwon Pharmaceuticals focuses on biopharmaceutical CDMO services and next-generation biopharmaceutical development. The CDMO business produces cGMP-grade plasmid DNA for gene therapies and DNA vaccines, while also advancing mRNA vaccine and therapeutic development through technology licensing. In new drug development, the company has completed clinical trials for DNA vaccines targeting MERS, Zika, and SFTS, and is expanding research through global partnerships.

Number of Employees

52people

Average Salary

70.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 11.934.0Point
PBR
2.14Industry Average 0.890.0Point

2.4x industry avg (risky)

ROE
-81.98Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
59.91Industry Average 12.430.0Point

4.8x industry avg (risky)

Trend 2023~20251.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼23.3% (2-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲4.3% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -61.4% (declining, 3yr)

Detailed News Sentiment

5 totalPositive 2Neutral 2Negative 1Average Sentiment Score 63

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 965Won52-week high 2,90052-week low 699
1-month return5.0Point

1m +11.05% (rising)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

11 totalPositive 1Neutral 10Negative 0
  • Neutral[첨부정정]의결권대리행사권유참고서류2026-06-01
  • Neutral기업지배구조보고서공시2026-06-01
  • Neutral[기재정정]주요사항보고서(자기전환사채매도결정)2026-05-29
  • Neutral[기재정정]주주총회소집공고2026-05-26
  • Neutral[기재정정]의결권대리행사권유참고서류2026-05-26